Your browser is no longer supported. Please, upgrade your browser.
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Quotes Basic TA News Snapshot
Total: 31 #1
TickerVLTC [NASD]
CompanyVoltari Corporation
CountryUSA
IndustryDiversified Communication Services
Market Cap4.87MEPS (ttm)-5.39
P/E-EPS this Y19.30%
Forward P/E-EPS next Y-
PEG-EPS past 5Y47.10%
P/S0.37EPS next 5Y25.00%
P/B-EPS Q/Q17.10%
Dividend-Sales Q/Q61.90%
Insider Own15.92%Inst Own21.40%
Insider Trans0.00%Inst Trans2.69%
Short Float10.19%Earnings-
Analyst Recom3.00Target Price1.79
Avg Volume56.09K52W Range0.63 - 3.67
Apr-01-15 10:07AMVoltari (VLTC) Stock is Soaring Today After Carl Icahn Discloses Stake at TheStreet
Apr-01-15 08:39AMUS STOCKS-Futures point to lower open after ADP report Reuters
Apr-01-15 07:17AMUS STOCKS-Futures flat at start of second quarter Reuters
Mar-31-15 06:07PMVoltari Surges 10%: Icahn Returns to Darling-Turned-Dog Motricity at Barrons.com
Mar-30-15 06:19PMVoltari Announces Closing of Rights Offering at noodls
Mar-30-15 05:50PMVoltari Announces Closing of Rights Offering GlobeNewswire
Mar-17-15 05:45PMVoltari Announces Extension of Rights Offering; Receipt of NASDAQ Notice of Non-Compliance at noodls
Mar-17-15 05:22PMVoltari Announces Extension of Rights Offering; Receipt of NASDAQ Notice of Non-Compliance GlobeNewswire
Voltari Corporation, together with its subsidiaries, provides relevance-driven mobile advertising, mobile marketing, mobile merchandising, and predictive analytics solutions for mobile operators, brands, and agencies. The company offers Voltari-Connect, a data management platform that provides targeting capabilities to identify and attract mobile audiences based on customer preferences and interests. It also offers solution consulting services comprising defining mobile trends, analyzing effectiveness of existing solutions, and recommending programs and solutions to enhance the mobile data subscriber experience. The company's solutions enable advertising agencies, consumer brands, and enterprises, and mobile operators to deliver mobile optimized, consumer-centric experiences that promote interaction, content consumption, and commerce across the mobile ecosystem. Voltari Corporation was founded in 2001 and is headquartered in New York, New York.
TickerDYAX [NASD]
CompanyDyax Corp.
CountryUSA
IndustryBiotechnology
Market Cap2.29BEPS (ttm)-0.09
P/E-EPS this Y65.40%
Forward P/E-EPS next Y73.70%
PEG-EPS past 5Y36.90%
P/S28.05EPS next 5Y18.60%
P/B21.76EPS Q/Q0.00%
Dividend-Sales Q/Q53.80%
Insider Own0.30%Inst Own97.30%
Insider Trans-36.93%Inst Trans-0.05%
Short Float3.65%EarningsApr 28/a
Analyst Recom1.60Target Price17.06
Avg Volume977.76K52W Range6.05 - 18.07
Apr-01-15Reiterated RBC Capital Mkts Outperform $18 → $31
Apr-01-15Reiterated Oppenheimer Outperform $14 → $26
Apr-01-15 10:15AMAnalysts Massively Increasing Dyax Price Targets at 24/7 Wall St.
Apr-01-15 09:18AMWed., April 1: Watch Monsanto Stock on Lower Earnings at MarketWatch
Apr-01-15 09:16AMADP: Private Payrolls Well Short of Expectation at MarketWatch
Apr-01-15 08:45AMTop Analyst Upgrades and Downgrades: Alibaba, Altera, Dyax, HP, Kinder Morgan, Kors, Staples, Twitter and More at 24/7 Wall St.
Apr-01-15 08:02AMDyax soars on positive drug test; Twitter, at MarketWatch
Apr-01-15 07:45AMThese ETFs Will Like the Dyax News
Mar-31-15 07:40PMDyax Corp, BioCryst Pharma Lead Tuesday's After-Hours Movers
Mar-31-15 05:53PMDyax shares soar on drug study, FDA fast track at MarketWatch
Mar-31-15 05:11PMWhy Dyax Will Dominate Biotech News on Wednesday at 24/7 Wall St.
Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders. It offers KALBITOR for the treatment of acute attacks of HAE. The company distributes KALBITOR through a network of wholesale, hospital, and specialty pharmacy arrangements. It is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b clinical study to treat HAE prophylactically. The company has agreements with CVie Therapeutics to develop and commercialize KALBITOR for the treatment of HAE and other angioedema indications in China, Hong Kong, and Macau; and Novellus Biopharma AG to develop and commercialize KALBITOR for the treatment of HAE and other angioedema indications in Latin America, including Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela. It also has agreement with CMIC Co., Ltd. to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other angioedema indications in Japan; and collaboration agreement with Sigma-Tau Rare Diseases S.A. to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other therapeutic indications in various territories worldwide. Dyax Corp. was founded in 1989 and is headquartered in Burlington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ashe Andrew D.General Counsel & EVPMar 06Sale15.502,40037,20034,127Mar 06 04:16 PM
ADELMAN BURT ACMO & EVP, R&DMar 05Sale15.669,375146,84328,125Mar 06 04:16 PM
MIGAUSKY GEORGE VEVP & Chief Financial OfficerMar 05Sale15.865,00079,28371,350Mar 06 04:15 PM
Christensen GustavCEO and PresidentMar 05Sale15.866,25099,111212,500Mar 06 04:17 PM
Ashe Andrew D.General Counsel & EVPFeb 26Sale15.341,50023,01036,527Feb 26 04:29 PM
TickerGDDY [NYSE]
CompanyGoDaddy
CountryUSA
IndustryInternet Information Providers
Market Cap-EPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own-
Insider Trans-Inst Trans-
Short Float-Earnings-
Analyst Recom-Target Price-
Avg Volume-52W Range- - -
Apr-01-15 10:17AMGoDaddy Shares Rev Up, Jumping 30% In Public Trading Debut at Forbes
Apr-01-15 10:14AMStocks lower amid economic reports; Dow falls 150 points at CNBC
Apr-01-15 10:13AMStocks are getting smashed - Dow down 160
Apr-01-15 09:44AMStocks to Watch: Wal-Mart, GoDaddy, Sears at The Wall Street Journal
Apr-01-15 09:39AMPisani's market open: Great start for Q2 IPO
Apr-01-15 09:07AMGoDaddy goes to Wall Street; Sears REIT plans; Mall owners call off deal
Apr-01-15 08:52AMStory Stocks from Briefing.com Briefing.com
Apr-01-15 08:15AMWall Street eyes jobs data, GoDaddy IPO at CNBC
Apr-01-15 08:13AMStocks extend slide; Private sector hiring slows; Walmart's political stand
Apr-01-15 07:58AMIf markets get volatile this quarter, this is how you hang on tight at MarketWatch
Leading provider of web registration and hosting services with 59 million domains.
TickerERII [NASD]
CompanyEnergy Recovery, Inc.
CountryUSA
IndustryPollution & Treatment Controls
Market Cap134.60MEPS (ttm)-0.36
P/E-EPS this Y-500.00%
Forward P/E-EPS next Y58.30%
PEG-EPS past 5Y-48.20%
P/S4.43EPS next 5Y20.00%
P/B1.92EPS Q/Q-169.20%
Dividend-Sales Q/Q-36.20%
Insider Own3.80%Inst Own31.30%
Insider Trans39.36%Inst Trans-3.98%
Short Float18.54%EarningsMay 06/a
Analyst Recom3.40Target Price3.50
Avg Volume267.69K52W Range2.49 - 6.18
Apr-01-15 08:40AMEnergy Recovery Commissions First IsoGenTM Turbogenerator System for Saudi Aramco at noodls
Apr-01-15 08:30AMEnergy Recovery Commissions First IsoGenTM Turbogenerator System for Saudi Aramco Business Wire
Mar-24-15 10:00AMEnergy Recovery Down to Strong Sell on Weak Q4 Results - Analyst Blog
Mar-23-15 09:24AMEnergy Recovery Named as Finalist for Technological Innovation of the Year at 2015 Pump Industry Awards at noodls
Mar-23-15 09:00AMEnergy Recovery Named as Finalist for Technological Innovation of the Year at 2015 Pump Industry Awards GlobeNewswire
Mar-20-15 08:30PMENERGY RECOVERY INVESTOR ALERT: Faruqi & Faruqi, LLP Notifies Investors With Losses in Excess of $100,000 to Contact the Firm Regarding Upcoming Lead Plaintiff Deadline in Class Action Against Energy Recovery, Inc. (ERII) Marketwired
Mar-18-15 08:51AMEnergy Recovery Secures $650,000 Desalination Order with Degremont Iberia for Mid-Size Plant in Spain at noodls
Mar-18-15 08:30AMEnergy Recovery Secures $650,000 Desalination Order with Degremont Iberia for Mid-Size Plant in Spain Business Wire
Mar-17-15 03:29PMERII SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against Energy Recovery, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of March 23, 2015 Business Wire
Mar-14-15 05:00AMSHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Energy Recovery, Inc. to Contact Brower Piven Before the March 23, 2015 Lead Plaintiff Deadline in Class Action Lawsuit -- ERII GlobeNewswire
Energy Recovery, Inc. designs, develops, and manufactures energy recovery devices (ERDs) to transform untapped energy into reusable energy from industrial fluid flows and pressure cycles. The company's products include PX ERDs and turbochargers for water desalination; AT and Halo turbochargers for low-pressure brackish and high-pressure seawater reverse osmosis systems; Pressure Exchanger energy recovery devices and turbochargers; and high-pressure pumps. It also offers IsoBoost energy recovery systems comprising turbines and industrial pumps; and lsoGen systems that enable oil and gas operators to capture hydraulic energy and generate electricity from high-pressure fluid flows. In addition, the company provides engineering, technical support, and training services; and preventive maintenance and support services, as well as reinstallation services. It serves engineering, procurement, and construction firms that design and build large desalination plants; original equipment manufacturers; and oil companies, and exploration and production companies. The company markets its products directly to customers through its sales organization, as well as through authorized independent sales agents in the United States and internationally. Energy Recovery, Inc. was founded in 1992 and is headquartered in San Leandro, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lorentzen Ole Peter10% OwnerMar 12Buy2.74200,000548,7608,490,334Mar 16 12:02 PM
BUEHLER ALEXANDER JDirectorMar 12Buy2.8715,00043,058120,000Mar 12 06:00 PM
Hanstveit ArveDirectorMar 12Sale2.8640,000114,5561,380,800Mar 13 05:41 PM
BUEHLER ALEXANDER JDirectorMar 11Buy2.8175,000211,068105,000Mar 12 06:00 PM
STROUD ANDREW B JRVP, Human ResourcesMar 11Buy2.831,7004,8081,700Mar 12 06:00 PM
TickerIMDZ [NASD]
CompanyImmune Design Corp.
CountryUSA
IndustryBiotechnology
Market Cap356.34MEPS (ttm)-1.82
P/E-EPS this Y-47.10%
Forward P/E-EPS next Y-15.20%
PEG-EPS past 5Y0.00%
P/S75.82EPS next 5Y5.00%
P/B3.24EPS Q/Q-111.50%
Dividend-Sales Q/Q2647.30%
Insider Own0.80%Inst Own90.00%
Insider Trans-67.60%Inst Trans0.68%
Short Float1.77%EarningsMar 31/a
Analyst Recom2.00Target Price36.00
Avg Volume54.40K52W Range11.51 - 40.13
Mar-31-15 05:58PMNasdaq stocks posting largest percentage decreases
Mar-31-15 05:13PMImmune Design reports 4Q loss
Mar-31-15 04:41PMImmune Design Announces Positive Topline Data From Three Phase 1 Clinical Trials of Immuno-Oncology Agents at noodls
Mar-31-15 04:41PMImmune Design Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update at noodls
Mar-31-15 04:30PMImmune Design Corp Earnings Call scheduled for 4:30 pm ET today
Mar-31-15 04:24PMIMMUNE DESIGN CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statem
Mar-31-15 04:12PM4:12 pm Immune Design announces positive topline data from three Phase 1 clinical trials of Immuno-Oncology agents; co also reported Q4 earnings
Mar-31-15 04:10PMImmune Design Announces Positive Topline Data From Three Phase 1 Clinical Trials of Immuno-Oncology Agents GlobeNewswire
Immune Design Corp., a clinical-stage immunotherapy company, focuses on the development of novel immune-based therapies based on its DCVex and GLAAS discovery platforms for cancer and other chronic conditions. Its product candidates in Phase I clinical trials comprise LV305, CMB305, and G305 for the treatment of solid tumor types, such as breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, or sarcoma; and G100 for the treatment of patients with merkel cell carcinoma. The company was founded in 2008 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ProQuest Investments IV, L.P.10% OwnerMar 25Sale27.564,956136,5872,414,040Mar 26 04:52 PM
ProQuest Investments IV, L.P.10% OwnerMar 24Sale27.6713,200365,2442,418,996Mar 26 04:52 PM
ProQuest Investments IV, L.P.10% OwnerMar 23Sale27.785,000138,9002,432,196Mar 23 05:10 PM
ProQuest Investments IV, L.P.10% OwnerMar 20Sale27.269,464257,9742,437,196Mar 23 05:10 PM
ProQuest Investments IV, L.P.10% OwnerMar 19Sale27.5530,000826,6042,446,660Mar 23 05:10 PM
TickerENRJ [AMEX]
CompanyEnerJex Resources, Inc.
CountryUSA
IndustryOil & Gas Refining & Marketing
Market Cap12.43MEPS (ttm)-0.05
P/E-EPS this Y183.30%
Forward P/E-EPS next Y-
PEG-EPS past 5Y14.90%
P/S0.81EPS next 5Y-
P/B0.27EPS Q/Q194.40%
Dividend-Sales Q/Q40.70%
Insider Own75.05%Inst Own41.30%
Insider Trans-Inst Trans0.90%
Short Float0.20%Earnings-
Analyst Recom-Target Price-
Avg Volume29.58K52W Range1.17 - 10.20
Apr-01-15 09:42AMEnerjex Resources Declares Monthly Cash Dividend on 10% Series a Preferred Stock at noodls
Apr-01-15 09:15AMEnerjex Resources Declares Monthly Cash Dividend on 10% Series a Preferred Stock Accesswire
Apr-01-15 08:30AMEnerjex Resources Announces Fourth Quarter and Year End Results Including a $5 Million Gain on Oil Hedges Accesswire
Mar-31-15 04:11PMENERJEX RESOURCES, INC. Files SEC form 10-K, Annual Report
Mar-13-15 01:03PMENERJEX RESOURCES, INC. Files SEC form 8-K/A, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financ
Mar-11-15 09:03AMENERJEX RESOURCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity S
Mar-11-15 09:00AMEnerjex Resources Announces Pricing of $3.1 Million Equity Offering at noodls
Mar-11-15 08:52AMEnerjex Resources Announces Pricing of $3.1 Million Equity Offering Accesswire
Mar-03-15 04:35PMEnerJex Resources Declares Monthly Cash Dividend On 10% Series A Preferred Stock at noodls
Mar-03-15 04:27PMEnerJex Resources Declares Monthly Cash Dividend On 10% Series A Preferred Stock Accesswire
EnerJex Resources, Inc., an independent energy company, acquires, develops, exploits, and produces crude oil and natural gas in the United States. It owns oil and gas leases covering approximately 100,000 acres in various prolific hydrocarbon basins located in Colorado, Kansas, Nebraska, and Texas. As of December 31, 2013, its total proved reserves consisted of 5.8 million barrels of oil equivalent. EnerJex Resources, Inc. is headquartered in San Antonio, Texas.
TickerOIBR [NYSE]
CompanyOi S.A.
CountryBrazil
IndustryDiversified Communication Services
Market Cap1.34BEPS (ttm)-0.08
P/E-EPS this Y-14.70%
Forward P/E-EPS next Y-17.40%
PEG-EPS past 5Y6.70%
P/S0.16EPS next 5Y-
P/B1.67EPS Q/Q-100.00%
Dividend-Sales Q/Q215.10%
Insider Own-Inst Own-
Insider Trans-Inst Trans-
Short Float1.83%Earnings-
Analyst Recom3.50Target Price1.75
Avg Volume3.91M52W Range1.54 - 3.69
Apr-01-15 07:53AMNotice to the Market - Reduction of Material Shareholding Interest at noodls
Apr-01-15 03:09AM3:09 am Oi SA annouces approval by Telemar Participacoes shareholders of the planned measures for the transaction goals published on February 20
Apr-01-15 01:03AMOi- Approval by Telemar Participacoes Shareholders of the Planned Measures for the Transaction Goals Published on February 20, 2014 PR Newswire
Apr-01-15 12:07AMMaterial Fact - Approval by Telemar ParticipaƧƵes Shareholders of the Planned Measures for the Transaction Goals Published on February 20, 2014 at noodls
Mar-30-15 07:28PMNotice to the Market - Reply to BM&FBOVESPA Official Letter at noodls
Mar-30-15 11:40AMBrazil Telecom Oi Sinks After Earnings Disappointment at Barrons.com
Mar-30-15 06:32AMOi SA downgraded by RBC Capital Mkts
Mar-27-15 09:34AMBrazil Surprise: Slight GDP Growth In 2014 at Barrons.com
Mar-27-15 03:36AM4Q14 and 2014 Press Release at noodls
Mar-26-15 09:05PMMaterial Fact - Approval at the Shareholders Meeting of Oi of the Terms and Conditions of the Exchange and Call Option Agreements at noodls
Oi S.A., through its subsidiaries, provides integrated telecommunication services for residential customers, companies, and governmental agencies in Brazil. It operates in three segments: Fixed-Line and Data Transmission Services, Mobile Services, and Other Services. The company offers fixed-line voice services, such as installation, monthly subscription, metered services, collect calls, and supplemental local services; domestic and international long-distance services; broadband Internet access services; subscription television services; and bundled services, as well as owns and operates public telephones. It also provides post-paid and pre-paid mobile voice and mobile data communications services; mobile long-distance services; value-added services, which include voice, text, and data applications consisting of voicemail, caller ID, personalization, text messaging subscription, chat, mobile television, and location-based services and applications; digital trunk services; and advanced voice services and voice portals, as well as leases digital and analog lines for use in private networks. Further, it provides mobile plans to small and medium-sized enterprises; data transmission services comprising interconnection between local area networks, videoconferencing, video/image transmission, and multimedia applications; information technology infrastructure services; data center services; managed services for mobile devices; interconnection and network usage charges, and traffic transportation services for other telecommunications providers; and ISP services, as well as operates an Internet portal and a call center. As of December 31, 2013, it had approximately 655,400 public telephones; and 11.6 million fixed lines in service in Region I and 6.7 million fixed lines in service in Region II. The company was formerly known as Brasil Telecom S.A. and changed its name to Oi S.A. in February 2012. Oi S.A. was founded in 1963 and is headquartered in Rio de Janeiro, Brazil.
TickerLTBR [NASD]
CompanyLightbridge Corp.
CountryUSA
IndustrySynthetics
Market Cap22.48MEPS (ttm)-0.31
P/E-EPS this Y16.20%
Forward P/E-EPS next Y-
PEG-EPS past 5Y15.50%
P/S17.29EPS next 5Y-
P/B3.88EPS Q/Q33.30%
Dividend-Sales Q/Q-33.30%
Insider Own13.15%Inst Own26.40%
Insider Trans0.00%Inst Trans131.63%
Short Float4.42%EarningsMar 25/a
Analyst Recom-Target Price-
Avg Volume41.72K52W Range1.03 - 3.54
Mar-31-15 01:04PMLIGHTBRIDGE CORP Financials
Mar-27-15 08:01AMLIGHTBRIDGE CORP Files SEC form 8-K, Change in Directors or Principal Officers
Mar-25-15 05:20PMLIGHTBRIDGE CORP Files SEC form 10-K, Annual Report
Mar-25-15 05:19PMLightbridge Announces Nuclear Fuel Development Update and 2014 Financial Results at noodls
Mar-25-15 05:00PMLightbridge Announces Nuclear Fuel Development Update and 2014 Financial Results GlobeNewswire
Mar-19-15 02:16PMLightbridge is Well Positioned to Improve Economics, Safety of Growing, Global Commercial Nuclear Power Market at noodls
Mar-11-15 06:49PMCEO Outlines Lightbridge's Near-Term Catalysts, Long-Term Growth at ROTH Conference at noodls
Mar-05-15 06:26PMCORRECTING and REPLACING -- Lightbridge to Host March 26 Conference Call and Webcast on 2014 Business Update and Fourth Quarter Financial Results at noodls
Mar-05-15 06:20PMCORRECTING and REPLACING -- Lightbridge to Host March 26 Conference Call and Webcast on 2014 Business Update and Fourth Quarter Financial Results GlobeNewswire
Mar-05-15 03:26PMLightbridge to Host March 26 Conference Call and Webcast on 2014 Business Update and Fourth Quarter Financial Results at noodls
Lightbridge Corporation, a nuclear fuel technology company, through its subsidiaries, participates in the nuclear power industry in the United States and internationally. It operates two segments, Technology and Consulting. The Technology segment engages in the design and development of proprietary nuclear fuels. Its primary fuel product lines include all-uranium seed and blanket fuel for existing plants; all-metal fuel for new build reactors; and thorium-based seed and blanket fuel for both existing and new build reactors. The Consulting segment provides nuclear power consulting and strategic advisory services to commercial and governmental entities. It offers integrated strategic advice across a range of areas, including regulatory development, nuclear reactor site selection, procurement and deployment, reactor and fuel technology, international relations, and regulatory affairs. The company was formerly known as Thorium Power, Ltd. and changed its name to Lightbridge Corporation in September 2009. Lightbridge Corporation was founded in 1992 and is based in McLean, Virginia.
TickerONVO [AMEX]
CompanyOrganovo Holdings, Inc.
CountryUSA
IndustryMedical Laboratories & Research
Market Cap284.83MEPS (ttm)-0.36
P/E-EPS this Y-34.60%
Forward P/E-EPS next Y-2.80%
PEG-EPS past 5Y0.00%
P/S712.07EPS next 5Y-
P/B5.90EPS Q/Q-28.60%
Dividend-Sales Q/Q100.00%
Insider Own8.60%Inst Own24.70%
Insider Trans-Inst Trans23.98%
Short Float22.61%EarningsFeb 09/a
Analyst Recom3.00Target Price-
Avg Volume1.13M52W Range3.29 - 9.25
Apr-01-15 08:20AMOrganovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue at noodls
Apr-01-15 08:09AM8:09 am Organovo presents data on in vitro three-dimensional kidney tissue at 2015 Experimental Biology Conf.
Apr-01-15 08:06AMORGANOVO HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Apr-01-15 08:05AMOrganovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue PR Newswire
Mar-22-15 05:22PMEXCLUSIVE: Organovo CEO Keith Murphy Talks Pipeline, Market Misconceptions
Mar-19-15 05:02PMORGANOVO HOLDINGS, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers
Mar-13-15 05:09PMORGANOVO HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Mar-13-15 11:35AMOrganovo Soothes Spooked Market
Mar-13-15 08:16AMOrganovo Provides Market Update at noodls
Mar-13-15 08:05AMOrganovo Provides Market Update PR Newswire
Organovo Holdings, Inc., a development-stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company is developing a suite of standardized and three-dimensional human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development; and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting and nerve grafts for nerve damage repair, as well as functional tissue patches for the repair or replacement of damaged tissues and organs. Organovo Holdings, Inc. has collaboration agreements with United Therapeutics Corporation; Knight Cancer Institute at Oregon Health & Science University; Michael J. Fox Foundation; Hoffman La Roche; Janssen Pharmaceuticals; and L'Oreal. The company was founded in 2007 and is headquartered in San Diego, California.
TickerTRIL [NASD]
CompanyTrillium Therapeutics Inc.
CountryCanada
IndustryBiotechnology
Market Cap-EPS (ttm)-2.44
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own-
Insider Trans-Inst Trans-
Short Float1.99%Earnings-
Analyst Recom-Target Price-
Avg Volume113.17K52W Range5.61 - 20.88
Apr-01-15 07:00AMTrillium Therapeutics Announces Pricing of Public Offering of Securities GlobeNewswire
Apr-01-15 06:58AM6:58 am Trillium Therapeutics prices 1.52 mln share common stock offering at $19.50/share
Mar-30-15 04:01PMTrillium Therapeutics Announces Proposed Public Offering of Securities GlobeNewswire
Mar-27-15 07:00AMTrillium Announces Appointment of Eric L. Sievers, M.D. as Chief Medical Officer GlobeNewswire
Mar-25-15 02:45PMTrillium Therapeutics to Present at the 5th Annual Cancer Immunotherapy Conference GlobeNewswire
Jan-28-15 01:55PMSo Far in 2015, This Choppy Market Is for Stock-Picker's Only at TheStreet
Dec-25-14 01:04PMTRILLIUM THERAPEUTICS INC Financials
Trillium Therapeutics Inc., a biopharmaceutical development company, advances cancer stem cell discoveries into novel and cancer therapies in Canada. Its products comprise Tigecycline, an antibiotic, which is in phase I for study in patients with relapsed or refractory acute myeloid leukemia (AML); SIRPaFc, an antibody-like fusion protein, which is in pre-clinical stage that blocks the activity of CD47, a molecule that is upregulated on cancer stem cells in AML and other tumors; CD200, a human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule; and TTI-1612, a recombinant soluble for the treatment of interstitial cystitis (IC), a chronic bladder disease characterized by low urinary HB-EGF levels and a dysfunctional, which recently completed a 28-patient Phase I trial in IC patients. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Toronto, Canada.
1 2 3 4 next